GEHC
GE HealthCare Technologies Inc.
GEHC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GEHC overall, supported by stronger fundamentals and stronger modeled upside.
GEHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
GEHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GEHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $71.95 | -12% |
| Forward | 15x | $81.84 | — |
| Current | 17x | $81.84 | — |
| Fair | 19x | $87.98 | +7.5% |
| Expensive | 24x | $111 | +36% |
Historical ranges are pointers, not guarantees.
GEHC's PE is in its fair range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over GEHC in the historical PE scenario, which offers more potential upside but is not a forecast.
GEHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GEHC, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GEHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.35 | +13% |
| Q3 2026 | $4.73 | -2.5% |
| Q2 2026 | $4.35 | -11% |
| Q1 2026 | $4.17 | -12% |
| Q4 2025 | $4.55 | +4.8% |
| Q3 2025 | $4.85 | +33% |
| Q2 2025 | $4.89 | +42% |
| Q1 2025 | $4.76 | +39% |
| Q4 2024 | $4.34 | +43% |
GEHC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GEHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.5B | +7.2% |
| Q2 2026 | $5.3B | +5.8% |
| Q1 2026 | $5.1B | +7.4% |
| Q4 2025 | $5.7B | +7.1% |
| Q3 2025 | $5.1B | +5.8% |
| Q2 2025 | $5B | +3.5% |
| Q1 2025 | $4.8B | +2.7% |
| Q4 2024 | $5.3B | +2.2% |
GEHC's revenue has grown year over year for 10 quarters in a row: $5.5B last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.9 points |
| Q2 2026 | 14% | +0.9 points |
| Q1 2026 | 10% | -3.1 points |
| Q4 2025 | 15% | -0.6 points |
| Q3 2025 | 13% | -1.2 points |
| Q2 2025 | 13% | +0.5 points |
| Q1 2025 | 13% | +1.6 points |
| Q4 2024 | 15% | +1.8 points |
GEHC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GEHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GEHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $793M | +64% |
| Q2 2026 | $68M | +750% |
| Q1 2026 | $112M | +14% |
| Q4 2025 | $916M | +13% |
| Q3 2025 | $483M | -26% |
| Q2 2025 | $8M | +$191M |
| Q1 2025 | $98M | -64% |
| Q4 2024 | $811M | -15% |
GEHC generated $1.9B in free cash flow over the past year, up 35% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GEHC on cash flow, with more consistent year-over-year improvement.
GEHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -1M shares |
| 1 year | -0.9% | -4M shares |
| 3 years | -1.1% | -5M shares |
| 5 years | -0.4% | -1.7M shares |
GEHC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $200M |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $100M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
GEHC spent $300M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GEHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.4x | Moderate |
GEHC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over GEHC on leverage, with a lower net debt burden relative to earnings.
GEHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 82.0 | Overbought |
GEHC's weekly RSI is 65 (neutral) and its Stochastic is 82 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GEHC PE vs Healthcare Sector
| Metric | GEHC | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 33% below |
| PE % | 42 | 42 | Same percentile |
GEHC is trading at 17x earnings, a 33% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over GEHC on valuation relative to its sector.
GEHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 13% above |
| 20 week MA | $69.5 | 18% above |
| 50 week MA | $72.1 | 13% above |
| 100 week MA | $74.2 | 10% above |
| 200 week MA | $76.6 | 6.9% above |
GEHC has climbed back above all five of its weekly moving averages, and it's now 6.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GEHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $58.4 | $77.3 | +32% |
| 2024 | $77.3 | $79.5 | +2.8% |
| 2025 | $79.5 | $83.6 | +5.2% |
| 2026 YTD | $83.6 | $81.8 | -2.1% |
GEHC has finished every year since 2023 higher, and it's down 2.1% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GEHC on returns for 2026, with the stronger performance.